Company intelligence / Profile preview

Corxel OM

United States

Ownership: Private
Development stage: Other

Overview

CX11 (VCT220), an oral small molecule GLP-1 RA, showed 9.4-9.7% weight loss in Phase 2 trial (China) at highest dose over 16 weeks with favorable safety; US Phase 2 trial first patient dosed, data expected H1 2026; Phase 3 ongoing in China.[1][2][3]

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Vincentage (licensor for CX11 ex-Greater China)

Beyond the preview

Go deeper on Corxel OM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corxel OM.

Explore the full profile